Tehlirian et al 2022_Suppplementary Material
收藏Mendeley Data2026-04-09 收录
官方服务：
资源简介：
Supplementary material for Tehlirian et al 2022 'Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study'
提供机构：
Sonya Frazier相关数据集
暂无相关数据集
